Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;60(5):620-632.
doi: 10.1111/apt.18138. Epub 2024 Jun 27.

Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease

Aakash Desai  1 , Jessica Petrov  1 , Jana G Hashash  1 , Harsh Patel  2 , Bhaumik Brahmbhatt  1 , Gursimran S Kochhar  3 , Francis A Farraye  1
Affiliations

Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease

Aakash Desai et al. Aliment Pharmacol Ther. 2024 Sep.

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RA) show anti-inflammatory properties.

Aim: To evaluate their clinical impact on inflammatory bowel disease (IBD) outcomes.

Methods: Retrospective cohort study utilising the TriNetX database comparing IBD-specific outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) and type 2 diabetes mellitus (T2DM) on GLP-1RA compared to oral hypoglycaemic agents. The primary outcome was hospitalisation requiring intravenous steroids and IBD-related surgery within 3 years. We performed 1:1 propensity score matching (PSM) for demographics, co-morbid conditions, BMI, laboratory values, HbA1c, and IBD medications including steroids.

Results: We identified 1130 patients in the UC GLP-1RA cohort (mean age: 58.9 ± 11.6 years, 56.3% female, 70.2% White, 57.2% with obesity) and 1140 patients in the CD GLP-1RA cohort (mean age: 56.7 ± 11.5, 61.9% female, 73.6% White, 56.2% with obesity). After PSM, there was no difference in the risk of intravenous steroid use (aHR: 1.21, 95% CI: 0.92-1.59) but a lower risk of colectomy (aHR: 0.37, 95% CI: 0.14-0.97) between the UC GLP-1RA and control cohort. There was no difference in the risk of intravenous steroid use (aHR: 1.04, 95% CI: 0.80-1.34) but a lower risk of surgery (aHR: 0.55, 95% CI: 0.36-0.84) between the CD GLP-1RA and CD control cohort. There was no difference in the risk of oral steroid use or advanced therapy initiation in the UC and CD GLP-1RA than control cohorts.

Conclusions: We found an association between lower risk of IBD-related surgery and GLP-1RA use for T2DM in patients with UC or CD.

PubMed Disclaimer

References

REFERENCES

    1. Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, et al. The anti‐inflammatory and immunological properties of GLP‐1 receptor agonists. Pharmacol Res. 2022;182:106320. https://doi.org/10.1016/j.phrs.2022.106320
    1. Azmy Nabeh O, Ishak Attallah M, El‐Sayed El‐Gawhary N. The pivotal relation between glucagon‐like peptides, NFκB and inflammatory bowel disease. Clin Exp Pharmacol Physiol. 2020;47(10):1641–1648. https://doi.org/10.1111/1440‐1681.13361
    1. Lourie J. A novel use of Liraglutide: induction of partial remission in ulcerative colitis and ankylosing spondylitis. Clin Dermatol. 2019;6:281. https://doi.org/10.23937/2378‐3656/1410281
    1. Kato S, Sato T, Fujita H, Kawatani M, Yamada Y. Effects of GLP‐1 receptor agonist on changes in the gut bacterium and the underlying mechanisms. Sci Rep. 2021;11(1):9167. https://doi.org/10.1038/s41598‐021‐88612‐x
    1. Hunt JE, Holst JJ, Jeppesen PB, Kissow H. GLP‐1 and intestinal diseases. Biomedicine. 2021;9(4):383. https://doi.org/10.3390/biomedicines9040383

Substances

LinkOut - more resources